glucose-1,6-bisphosphate has been researched along with B16 Melanoma in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beitner, R; Glass-Marmor, L; Morgenstern, H | 1 |
Beitner, R; Glass-Marmor, L | 1 |
Beitner, R; Karniel, M | 1 |
3 other study(ies) available for glucose-1,6-bisphosphate and B16 Melanoma
Article | Year |
---|---|
Calmodulin antagonists decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability of melanoma cells.
Topics: Adenosine Triphosphate; Animals; Benzimidazoles; Calmodulin; Cell Survival; Clotrimazole; Fructosediphosphates; Glucose; Glucose-6-Phosphate; Imidazoles; Melanoma, Experimental; Mice; Thioridazine; Tumor Cells, Cultured | 1996 |
Taxol (paclitaxel) induces a detachment of phosphofructokinase from cytoskeleton of melanoma cells and decreases the levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate and ATP.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Cell Survival; Cytoskeleton; Dose-Response Relationship, Drug; Fructosediphosphates; Glucose-6-Phosphate; Glycolysis; Melanoma, Experimental; Mice; Paclitaxel; Phosphofructokinase-1 | 1999 |
Local anesthetics induce a decrease in the levels of glucose 1, 6-bisphosphate, fructose 1,6-bisphosphate, and ATP, and in the viability of melanoma cells.
Topics: Adenosine Triphosphate; Anesthetics, Local; Animals; Antineoplastic Agents; Bupivacaine; Cell Death; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Fructosediphosphates; Glucose-6-Phosphate; Glycolysis; Lidocaine; Melanoma, Experimental; Mice; Time Factors; Tumor Cells, Cultured | 2000 |